Replies to post #102240 on Biotech Values

[DewDiligence]

The interest in IL-28B is sufficiently recent that completed HCV studies with DAA’s have only haphazard data, at best, on the effect of the gene variants.

Also if you were a CC and had an 80% chance of SVR would they even use a DAA?

I do not understand your question—can you rephrase it?

[DewDiligence]

DGX launches IL28B diagnostic for HCV treatment:

http://finance.yahoo.com/news/Quest-Diagnostics-Launches-prnews-1069288880.html?x=0&.v=1

DGX licensed the IL28B IP from MRK.